Consistent with a protective action of endogenous kinins and B2R activation in diabetic nephropathy, the beneficial effect of ACE inhibition is suppressed by a B2R antagonist in mice or rats [52,53]. Here, BDKRB2 is linked to diabetic kidney disease.